Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 38.1% during mid-day trading on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. Approximately 605,625 shares traded hands during trading, an increase of 51% from the average daily volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The stock has a market cap of C$12.63 million, a PE ratio of -7.25 and a beta of 0.20. The firm has a fifty day moving average price of C$0.09 and a 200 day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How to Choose Top Rated Stocks
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Using the MarketBeat Dividend Tax Calculator
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Why Are These Companies Considered Blue Chips?
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
